Smith Shellnut Wilson’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-9,449
| Closed | -$273K | – | 150 |
|
|
2024
Q3 | $273K | Hold |
9,449
| – | – | 0.12% | 117 |
|
|
2024
Q2 | $264K | Sell |
9,449
-6,032
| -39% | -$166K | 0.13% | 114 |
|
|
2024
Q1 | $430K | Hold |
15,481
| – | – | 0.23% | 79 |
|
|
2023
Q4 | $446K | Hold |
15,481
| – | – | 0.26% | 71 |
|
|
2023
Q3 | $514K | Hold |
15,481
| – | – | 0.31% | 58 |
|
|
2023
Q2 | $568K | Hold |
15,481
| – | – | 0.32% | 57 |
|
|
2023
Q1 | $632K | Hold |
15,481
| – | – | 0.38% | 50 |
|
|
2022
Q4 | $793K | Sell |
15,481
-258
| -2% | -$12.4K | 0.49% | 38 |
|
|
2022
Q3 | $689K | Hold |
15,739
| – | – | 0.46% | 40 |
|
|
2022
Q2 | $825K | Hold |
15,739
| – | – | 0.51% | 39 |
|
|
2022
Q1 | $815K | Sell |
15,739
-699
| -4% | -$36.3K | 0.43% | 42 |
|
|
2021
Q4 | $971K | Hold |
16,438
| – | – | 0.48% | 47 |
|
|
2021
Q3 | $707K | Hold |
16,438
| – | – | 0.41% | 46 |
|
|
2021
Q2 | $644K | Hold |
16,438
| – | – | 0.37% | 53 |
|
|
2021
Q1 | $596K | Sell |
16,438
-2,329
| -12% | -$82.7K | 0.36% | 52 |
|
|
2020
Q4 | $691K | Sell |
18,767
-1,013
| -5% | -$37.2K | 0.41% | 47 |
|
|
2020
Q3 | $689 | Buy |
19,780
+736
| +4% | +$25.8K | 0.26% | 51 |
|
|
2020
Q2 | $591K | Hold |
19,044
| – | – | 0.42% | 45 |
|
|
2020
Q1 | $590K | Sell |
19,044
-28
| -0.1% | -$954 | 0.49% | 38 |
|
|
2019
Q4 | $709K | Buy |
19,072
+103
| +0.5% | +$3.67K | 0.47% | 40 |
|
|
2019
Q3 | $647K | Buy |
18,969
+1
| +0% | +$36 | 0.48% | 40 |
|
|
2019
Q2 | $780K | Sell |
18,968
-1,008
| -5% | -$40K | 0.59% | 34 |
|
|
2019
Q1 | $805K | Buy |
19,976
+1
| +0% | +$40 | 0.64% | 35 |
|
|
2018
Q4 | $827K | Buy |
19,975
+1
| +0% | +$42 | 0.89% | 23 |
|
|
2018
Q3 | $835K | Buy |
+19,974
| New | +$769K | 0.75% | 27 |
|
|
2018
Q1 | $798K | Buy |
23,687
+2
| +0% | +$69 | 0.69% | 28 |
|
|
2017
Q4 | $814K | Buy |
23,685
+1
| +0% | +$34 | 0.69% | 27 |
|
|
2017
Q3 | $802K | Buy |
23,684
+6
| +0% | +$193 | 0.71% | 24 |
|
|
2017
Q2 | $791K | Sell |
23,678
-3
| -0% | -$95 | 0.82% | 24 |
|
|
2017
Q1 | $769K | Buy |
23,681
+1
| +0% | +$32 | 0.71% | 25 |
|
|
2016
Q4 | $730K | Buy |
+23,680
| New | +$723K | 0.7% | 27 |
|
Other funds holding PFE
Smith Shellnut Wilson's PFE Position: Q4 2024 in Review
Smith Shellnut Wilson sold out of Pfizer (PFE) in Q4 2024, closing a stake of 9,449 shares — an estimated $273K sold.
Smith Shellnut Wilson first reported a position in PFE in Q4 2016 and held it in 31 quarters. The position peaked at $971K in Q4 2021. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Smith Shellnut Wilson reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
- Smith Shellnut Wilson sold 9,449 Pfizer shares in Q4 2024, an estimated $273K.
- Smith Shellnut Wilson first reported a position in Pfizer in Q4 2016 and held it in 31 quarters.
- Smith Shellnut Wilson's Pfizer position peaked at $971K in Q4 2021.
- 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Smith Shellnut Wilson's 13F filing for Q4 2024, filed 4 Mar 2025.